What is Immuron?
Founded in 1994, Immuron operates as a publicly listed biopharmaceutical innovator specializing in the development and commercialization of oral immunotherapy solutions. The company's core competency lies in its unique platform technology, which utilizes polyclonal antibodies to address high-unmet-need areas such as infectious diseases and inflammatory disorders. As a clinical-stage enterprise, Immuron bridges the gap between laboratory discovery and commercial application, maintaining a robust portfolio of assets designed to provide targeted, non-invasive treatment options. Its strategic focus on oral delivery mechanisms distinguishes it from traditional injectable therapies, offering a competitive advantage in patient compliance and therapeutic efficacy within the biotechnology landscape.
How much funding has Immuron raised?
Immuron has raised a total of $26.1M across 2 funding rounds:
Stock Offering
$6.1M
Other Financing Round
$20M
Stock Issuance/Offering (2017): $6.1M, investors not publicly disclosed
Other Financing Round (2020): $20M, investors not publicly disclosed
Key Investors in Immuron
Immuron
Undisclosed investor participating in the funding round.
Immuron
Undisclosed investor participating in the funding round.
Immuron
Undisclosed investor participating in the funding round.
What's next for Immuron?
With the recent infusion of capital, Immuron is well-positioned to transition its lead candidates through advanced clinical trials and toward potential regulatory approval. The strategic roadmap likely involves expanding the reach of its existing commercial products while simultaneously investing in the pipeline of novel antibody-based therapies. As the company moves into this next phase of development, the focus will remain on operational excellence and the successful execution of its clinical milestones. Investors and industry stakeholders will be monitoring the firm's ability to translate this financial support into tangible therapeutic outcomes, which will be essential for long-term value creation and sustained market leadership in the biopharmaceutical space.
See full Immuron company page
